The Misuse of Drugs Regulations 2001 © Crown Copyright 2001 Statutory Instruments printed from this website are printed under the superintendence and authority of the Controller of HMSO being the Queen's Printer of Acts of Parliament. The legislation contained on this web site is subject to Crown Copyright protection. It may be reproduced free of charge provided that it is reproduced accurately and that the source and copyright status of the material is made evident to users. It should be noted that the right to reproduce the text of Statutory Instruments does not extend to the Queen's Printer imprints which should be removed from any copies of the Statutory Instrument which are issued or made available to the public. This includes reproduction of the Statutory Instrument on the Internet and on intranet sites. The Royal Arms may be reproduced only where they are an integral part of the original document. The text of this Internet version of the Statutory Instrument which is published by the Queen's Printer of Acts of Parliament has been prepared to reflect the text as it was Made. A print version is also available and is published by The Stationery Office Limited as the The Misuse of Drugs Regulations 2001, ISBN 0 11 039021 0. The print version may be purchased by clicking here. Braille copies of this Statutory Instrument can also be purchased at the same price as the print edition by contacting TSO Customer Services on 0870 600 5522 or e-mail:customer.services@tso.co.uk. Further information about the publication of legislation on this website can be found by referring to the Frequently Asked Questions. To ensure fast access over slow connections, large documents have been segmented into "chunks". Where you see a "continue" button at the bottom of the page of text, this indicates that there is another chunk of text available.
The Secretary of State, in exercise of the powers conferred on him by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971[1], after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 31(3) of that Act, hereby makes the following Regulations: Citation and commencement 1. These Regulations may be cited as the Misuse of Drugs Regulations 2001 and shall come into force on 1st February 2002. Interpretation 2. - (1) In these Regulations, unless the context otherwise requires -
(b) the controlled drug in any component part is packaged in such a form, or in combination with other active or inert substances in such a manner, that it cannot be recovered by readily applicable means or in a yield which constitutes a risk to health; and (c) no one component part of the product or preparation contains more than one milligram of the controlled drug or one microgram in the case of lysergide or any other N-alkyl derivative of lysergamide;
(2) In these Regulations any reference to a regulation or schedule shall be construed as a reference to a regulation contained in these Regulations or, as the case may be, to a schedule to these Regulations, and any reference in a regulation or schedule to a paragraph shall be construed as a reference to a paragraph of that regulation or schedule.
(b) the drugs specified in Schedule 5.
(4) Sections 4(1) (which prohibits the production and supply of controlled drugs) and 5(1) of the Act shall not have effect in relation to poppy-straw.
(b) a person engaged in the business of a carrier when acting in the course of that business; (c) a person engaged in the business of the Post Office when acting in the course of that business; (d) an officer of customs and excise when acting in the course of his duty as such; (e) a person engaged in the work of any laboratory to which the drug has been sent for forensic examination when acting in the course of his duty as a person so engaged; (f) a person engaged in conveying the drug to a person who may lawfully have that drug in his possession.
Administration of drugs in Schedules 2, 3, 4 and 5
(b) a person lawfully conducting a retail pharmacy business and acting in his capacity as such may, at the registered pharmacy at which he carries on that business, manufacture or compound any drug specified in Schedule 2 or 5.
(2) Notwithstanding the provisions of section 4(1)(b) of the Act, any of the following persons, that is to say -
(b) a pharmacist; (c) a person lawfully conducting a retail pharmacy business; (d) the person in charge or acting person in charge of a hospital or nursing home which is wholly or mainly maintained by a public authority out of public funds or by a charity or by voluntary subscriptions; (e) in the case of such a drug supplied to her by a person responsible for the dispensing and supply of medicines at the hospital or nursing home, the sister or acting sister for the time being in charge of a ward, theatre or other department in such a hospital or nursing home as aforesaid; (f) a person who is in charge of a laboratory the recognised activities of which consist in, or include, the conduct of scientific education or research and which is attached to a university, university college or such a hospital as aforesaid or to any other institution approved for the purpose under this sub-paragraph by the Secretary of State; (g) a public analyst appointed under section 27 of the Food Safety Act 1990[11]; (h) a sampling officer within the meaning of Schedule 3 to the Medicines Act 1968; (i) a person employed or engaged in connection with a scheme for testing the quality or amount of the drugs, preparations and appliances supplied under the National Health Service Act 1977 or the National Health Service (Scotland) Act 1978 and the regulations made thereunder; (j) a person authorised by the Pharmaceutical Society of Great Britain for the purposes of section 108 or 109 of the Medicines Act 1968,
may, when acting in his capacity as such, supply or offer to supply any drug specified in Schedule 2 or 5 to any person who may lawfully have that drug in his possession, except that nothing in this paragraph authorises -
(ii) a sister or acting sister for the time being in charge of a ward, theatre or other department to supply any drug otherwise than for administration to a patient in that ward, theatre or department in accordance with the directions of a doctor or dentist.
(3) Notwithstanding the provisions of section 4(1)(b) of the Act, a person who is authorised as a member of a group may, under and in accordance with the terms of his group authority and in compliance with any conditions attached thereto, supply or offer to supply any drug specified in Schedule 2 or 5 to any person who may lawfully have that drug in his possession.
(b) the installation manager of an offshore installation,
may supply or offer to supply any drug specified in Schedule 2 or 5 -
(ii) to any person who may lawfully supply that drug to him; (iii) to any constable for the purpose of the destruction of that drug.
(6) The provisions referred to in paragraph (5) are any provision of, or of any instrument which is in force under -
(b) the Health and Safety at Work etc. Act 1974[12] or (c) the Merchant Shipping Act 1995.
Production and supply of drugs in Schedules 3 and 4
(b) a person lawfully conducting a retail pharmacy business and acting in his capacity as such may, at the registered pharmacy at which he carries on that business, manufacture or compound any drug specified in Schedule 3 or 4; (c) a person who is authorised by a written authority issued by the Secretary of State under and for the purposes of this sub-paragraph and for the time being in force may, at the premises specified in that authority and in compliance with any conditions so specified, produce any drug specified in Schedule 3 or 4.
(2) Notwithstanding the provisions of section 4(1)(b) of the Act, any of the following persons, that is to say -
(b) a pharmacist; (c) a person lawfully conducting a retail pharmacy business; (d) a person in charge of a laboratory the recognised activities of which consist in, or include, the conduct of scientific education or research; (e) a public analyst appointed under section 27 of the Food Safety Act 1990; (f) a sampling officer within the meaning of Schedule 3 to the Medicines Act 1968; (g) a person employed or engaged in connection with a scheme for testing the quality or amount of the drugs, preparations and appliances supplied under the National Health Service Act 1977 or the National Health Service (Scotland) Act 1978 and the regulations made thereunder; (h) a person authorised by the Pharmaceutical Society of Great Britain for the purposes of section 108 or 109 of the Medicines Act 1968,
may, when acting in his capacity as such, supply or offer to supply any drug specified in Schedule 3 or 4 to any person who may lawfully have that drug in his possession.
(b) the person in charge or acting person in charge of a hospital or nursing home; (c) in the case of such a drug supplied to her by a person responsible for the dispensing and supply of medicines at that hospital or nursing home, the sister or acting sister for the time being in charge of a ward, theatre or other department in a hospital or nursing home,
may, when acting in his capacity as such, supply or offer to supply any drug specified in Schedule 3, or any drug specified in Schedule 4 which is contained in a medicinal product, to any person who may lawfully have that drug in his possession, except that nothing in this paragraph authorises -
(ii) a sister or acting sister for the time being in charge of a ward, theatre or other department to supply any drug otherwise than for administration to a patient in that ward, theatre or department in accordance with the directions of a doctor or dentist.
(4) Notwithstanding the provisions of section 4(1)(b) of the Act -
(b) a person who is authorised under paragraph (1)(c ) may supply or offer to supply any drug which he may, by virtue of being so authorised, lawfully produce to any person who may lawfully have that drug in his possession.
(5) Notwithstanding the provisions of section 4(1)(b) of the Act -
(b) the installation manager of an offshore installation,
may supply or offer to supply any drug specified in Schedule 3, or any drug specified in Schedule 4 which is contained in a medicinal product -
(ii) to any person who may lawfully supply that drug to him.
(6) Notwithstanding the provisions of section 4(1)(b) of the Act, a person in charge of a laboratory may, when acting in his capacity as such, supply or offer to supply any drug specified in Schedule 3 which is required for use as a buffering agent in chemical analysis to any person who may lawfully have that drug in his possession.
(b) a person specified in one of sub-paragraphs (a) to (h) of regulation 9(2) may have in his possession any drug specified in Schedule 3 or 4; (c) a person specified in regulation 9(3)(b) or (c ) or (6) may have in his possession any drug specified in Schedule 3,
for the purpose of acting in his capacity as such a person, except that nothing in this paragraph authorises -
(ii) a person specified in sub-paragraph (c ) of regulation 9(3); or (iii) a person specified in regulation 9(6),
to have in his possession any drug other than such a drug as is mentioned in the paragraph or sub-paragraph in question specifying him.
(b) that or any other person on his behalf made a declaration or statement, which was false in any particular, for the purpose of obtaining the supply or prescription.
(3) Notwithstanding the provisions of section 5(1) of the Act, a person who is authorised as a member of a group may, under and in accordance with the terms of his group authority and in compliance with any conditions attached thereto, have any drug specified in Schedule 2, 3 or Part I of Schedule 4 in his possession.
(b) a person who is authorised under regulation 9(1)(c ) may have in his possession any drug which he may, by virtue of being so authorised, lawfully produce; (c) a person who is authorised under regulation 9(4)(a) may have in his possession any drug which he may, by virtue of being so authorised, lawfully supply or offer to supply.
(5) Notwithstanding the provisions of section 5(1) of the Act -
(b) the master of a foreign ship which is in a port in Great Britain may have in his possession any drug specified in Schedule 2, 3 or Part I of Schedule 4 so far as necessary for the equipment of the ship.
(6) The foregoing provisions of this regulation are without prejudice to the provisions of regulation 4(3)(a).
(b) so far as necessary as aforesaid, administer; and (c) surrender to the appropriate medical officer such stocks in her possession as are no longer required by her of,
any controlled drug which she may, under and in accordance with the provisions of the Medicines Act 1968 and of any instrument which is in force thereunder, lawfully administer.
(b) for the purposes of paragraph (2), a person appointed under and in accordance with section 15 of the Act of 1997 by that authority to exercise supervision over registered midwives within their area, who is for the time being authorised as aforesaid;
Cultivation under licence of cannabis plant
(b) is not authorised by any provision of these Regulations other than the provisions of regulation 6(6) and (7)(f) to have that drug in his possession,
unless that person produces to the supplier a statement in writing signed by the recipient to the effect that he is empowered by the recipient to receive that drug on behalf of the recipient, and the supplier is reasonably satisfied that the document is a genuine document.
(ii) states the name, address and profession or occupation of the recipient; (iii) specifies the purpose for which the drug supplied is required and the total quantity to be supplied; and (iv) where appropriate, satisfies the requirements of paragraph (5);
(b) unless he is reasonably satisfied that the signature is that of the person purporting to have signed the requisition and that that person is engaged in the profession or occupation specified in the requisition,
except that where the recipient is a practitioner and he represents that he urgently requires a controlled drug for the purpose of his profession, the supplier may, if he is reasonably satisfied that the recipient so requires the drug and is, by reason of some emergency, unable before delivery to furnish to the supplier a requisition in writing duly signed, deliver the drug to the recipient on an undertaking by the recipient to furnish such a requisition within the twenty-four hours next following.
(b) the person in charge or acting person in charge of a hospital or nursing home; (c) a person who is in charge of a laboratory; (d) the owner of a ship, or the master of a ship which does not carry a doctor among the seamen employed in it; (e) the master of a foreign ship in a port in Great Britain; (f) the installation manager of an offshore installation.
(5) A requisition furnished for the purposes of paragraph (2) shall -
(b) where furnished by the master of a foreign ship, contain a statement, signed by the proper officer of the port health authority, or, in Scotland, the medical officer designated under section 14 of the National Health Service (Scotland) Act 1978 by the Health Board, within whose jurisdiction the ship is, that the quantity of the drug to be supplied is the quantity necessary for the equipment of the ship.
(6) Where the person responsible for the dispensing and supply of medicines at any hospital or nursing home supplies a controlled drug to the sister or acting sister for the time being in charge of any ward, theatre or other department in that hospital or nursing home (hereafter in this paragraph referred to as "the recipient") he shall -
(b) mark the requisition in such manner as to show that it has been complied with,
and any requisition obtained for the purposes of this paragraph shall be retained in the dispensary at which the drug was supplied and a copy of the requisition or a note of it shall be retained or kept by the recipient.
(b) any drug specified in Schedule 3 contained in or comprising a preparation which -
(ii) has present in it both a substance specified in paragraph 1 or 2 of that Schedule and a salt of that substance; and (iii) is pre-mixed in a kit;
(c) any exempt product.
Form of prescriptions
(b) insofar as it specifies the information required by sub-paragraphs (e) and (f) below to be specified, be written by the person issuing it in his own handwriting; (c) except in the case of a health prescription, specify the address of the person issuing it; (d) if issued by a dentist, have the words "for dental treatment only" written on it and, if issued by a veterinary surgeon or a veterinary practitioner, have a declaration written on it that the controlled drug is prescribed for an animal or herd under his care; (e) specify the name and address of the person for whose treatment it is issued or, if it is issued by a veterinary surgeon or veterinary practitioner, of the person to whom the controlled drug prescribed is to be delivered; (f) specify the dose to be taken and -
(ii) in any other case, the total quantity (in both words and figures ) of the controlled drug to be supplied;
(g) in the case of a prescription for a total quantity intended to be supplied by instalments, contain a direction specifying the amount of the instalments of the total amount which may be supplied and the intervals to be observed when supplying.
(2) Paragraph (1)(b) shall not have effect in relation to -
(b) a prescription containing no controlled drug other than -
(ii) phenobarbitone sodium; or (iii) a preparation containing a drug specified in paragraph (i) or (ii) above.
(3) In the case of a prescription issued for the treatment of a patient in a hospital or nursing home, it shall be a sufficient compliance with paragraph (1)(e) if the prescription is written on the patient's bed card or case sheet.
(b) unless the address specified in the prescription as the address of the person issuing it is an address within the United Kingdom; (c) unless he either is acquainted with the signature of the person by whom it purports to be issued and has no reason to suppose that it is not genuine, or has taken reasonably sufficient steps to satisfy himself that it is genuine; (d) before the date specified in the prescription; (e) subject to paragraph (3), later than thirteen weeks after the date specified in the prescription.
(2) Subject to paragraphs (3) and (4), a person supplying on prescription a controlled drug other than a drug specified in Schedule 4 or 5 shall, at the time of the supply, mark on the prescription the date on which the drug is supplied and, unless it is a health prescription, shall retain the prescription on the premises from which the drug was supplied.
(b) paragraph (2) shall have effect as if for the words "at the time of the supply" there were substituted the words "on each occasion on which an instalment is supplied".
Exemption for certain prescriptions
(b) in the case of a controlled drug which is a preparation -
(ii) not made up as aforesaid, with the total amount of the preparation in the bottle, package or other container and the percentage of each of its components which is a controlled drug.
(2) Nothing in this regulation shall have effect in relation to -
(b) any drug specified in Schedule 3 contained in or comprising a preparation which -
(ii) has present in it both a substance specified in paragraph 1 or 2 of that Schedule and a salt of that substance; and (iii) is premixed in a kit;
(c) any exempt product;
(3) In this regulation, the expressions "clinical trial" and "medicinal test on animals" have the same meanings as in the Medicines Act 1968.
(b) he shall use a separate register or separate part of the register for entries made in respect of each class of drugs, and each of the drugs specified in paragraphs 1 and 3 of Schedule 1 and paragraphs 1, 3 and 6 of Schedule 2 together with its salts and any preparation or other product containing it or any of its salts shall be treated as a separate class, so however that any stereoisomeric form of a drug or its salts shall be classed with that drug.
(2) Nothing in paragraph (1) shall be taken as preventing the use of a separate section within a register or separate part of a register in respect of different drugs or strengths of drugs comprised within the class of drugs to which that register or separate part relates.
(b) a person licensed under regulation 5 to supply any drug, where the licence so directs; or (c) the sister or acting sister for the time being in charge of a ward, theatre or other department in a hospital or nursing home.
Requirements as to registers
(b) every entry required to be made under regulation 19 in such a register shall be made on the day on which the drug is obtained or, as the case may be, on which the transaction in respect of the supply of the drug by the person required to make the entry takes place or, if that is not reasonably practicable, on the day next following that day; (c) no cancellation, obliteration or alteration of any such entry shall be made, and a correction of such an entry shall be made only by way of marginal note or footnote which shall specify the date on which the correction is made; (d) every such entry and every correction of such an entry shall be made in ink or otherwise so as to be indelible; (e) such a register shall not be used for any purpose other than the purposes of these Regulations; (f) a separate register shall be kept in respect of each premises at which the person required to keep the register carries on his business or occupation, but subject to that not more than one register shall be kept at one time in respect of each class of drugs in respect of which he is required to keep a separate register, so, however, that a separate register may, with the approval of the Secretary of State, be kept in respect of each department of the business carried on by him; (g) every such register in which entries are currently being made shall be kept at the premises to which it relates.
Record-keeping requirements in respect of drugs in Schedule 2 in particular cases
(b) on administering such a drug to a patient, enter in the said book as soon as practicable the name and address of the patient, the amount administered and the form in which it was administered.
Record-keeping requirements in respect of drugs Schedules 3 and 4
(b) for the purpose of confirming any such particulars, produce any stock of such drugs in his possession; (c) produce any register, book or document required to be kept under these Regulations relating to any dealings in controlled drugs which is in his possession.
(2) The persons referred to in paragraph (1) are -
(b) any person authorised by or under any provision of the Act to import or export any controlled drug; (c) a wholesale dealer; (d) a retail dealer; (e) a practitioner; (f) the person in charge or acting person in charge of a hospital or nursing home; (g) a person who is in charge of a laboratory; (h) a person who is authorised under regulation 9(4)(a) to supply any controlled drug.
(3) Nothing in this regulation shall require the furnishing of personal records which a person has acquired or created in the course of his profession or occupation and which he holds in confidence; and in this paragraph "personal records" means documentary and other records concerning an individual (whether living or dead) who can be identified from them and relating to his physical or mental health.
(b) in any other case, for the said sub-paragraphs (a) and (b) there were substituted the words "unless the prescription complies with the provisions of the Misuse of Drugs Regulations 1985 relating to prescriptions".
1. The following substances and products, namely -
Cannabinol Cannabinol derivatives not being dronabinol or its stereoisomers Cannabis and cannabis resin Cathinone Coca leaf Concentrate of poppy-straw Eticyclidine Etryptamine Lysergamide Lysergide and other N-alkyl derivatives of lysergamide Mescaline Methcathinone Psilocin Raw opium Rolicyclidine Tenocyclidine 4-Bromo-2,5-dimethoxy-a-methylphenethylamine N,N-Diethyltryptamine N,N-Dimethyltryptamine 2,5-Dimethoxy- ,4-dimethylphenethylamineN-Hydroxy-tenamphetamine 4-Methyl-aminorex (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent; (c) the following phenethylamine derivatives, namely - Allyl( -methyl-3,4-methylenedioxyphenethyl)amine2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol 2-Amino-1-(3,4-dimethoxyphenyl)ethanol Benzyl( -methyl-3,4-methylenedioxyphenethyl)amine4-Bromo-ß,2,5-trimethoxyphenethylamine N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine Cyclopropylmethyl( -methyl-3,4-methylenedioxyphenethyl)amine2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)ethylamine 2-(4,7-Dimethoxy-2,3-dihydro-1H-indan-5-yl)-1-methylethylamine 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine 2-(1,4-Dimethoxy-2-naphthyl)ethylamine 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine , -Dimethyl-3,4-methylenedioxyphenethylamine , -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amineDimethyl( -methyl-3,4-methylenedioxyphenethyl)amineN-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine 4-Iodo-2,5-dimethoxy-a-methylphenethyl(dimethyl)amine 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine 2-Methoxyethyl( -methyl-3,4-methylenedioxyphenethyl)amine2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine ß-Methoxy-3,4-methylenedioxyphenethylamine 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine 2-( -Methyl-3,4-methylenedioxyphenethylamino)ethanol -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amineN-Methyl-N-( -methyl-3,4-methylenedioxyphenethyl)hydroxylamineO-Methyl-N-( -methyl-3,4-methylenedioxyphenethyl)hydroxylamine -Methyl-4-(methylthio)phenethylamineß,3,4,5-Tetramethoxyphenethylamine ß,2,5-Trimethoxy-4-methylphenethylamine (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an N-alkylphenethylamine, -methylphenethylamine, an N-alkyl- -methylphenethylamine, -ethylphenethylamine, or an N-alkyl- -ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;(e) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from fentanyl by modification in any of the following ways, that is to say -
(ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups; (iii) by substitution in the piperidine ring with alkyl or alkenyl groups; (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups; (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group; (vi) by replacement of the N-propionyl group by another acyl group;
(f) any compound (not being a compound for the time being specified in Schedule 2) structurally derived from pethidine by modification in any of the following ways, that is to say -
(ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted; (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups; (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group; (v) by formation of an N-oxide or of a quaternary base.
2.
Any stereoisomeric form of a substance specified in paragraph 1. 1. The following substances and products, namely -
2. Any stereoisomeric form of a substance specified in paragraph 1 not being dextromethorphan or dextrorphan. 3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6. 4. Any salt of a substance specified in any of paragraphs 1 to 3. 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5. 6. The following substances and products, namely -
7. Any stereoisomeric form of a substance specified in paragraph 6. 8. Any salt of a substance specified in paragraph 6 or 7. 9. Any preparation or other product containing a substance or product specified in any of paragraphs 6 to 8, not being a preparation specified in Schedule 5. 1. The following substances, namely -
2.
Any stereoisomeric form of a substance specified in paragraph 1 not being phenylpropanolamine. 1. The following substances and products, namely -
2. Any stereoisomeric form of a substance specified in paragraph 1. 3. Any salt of a substance specified in paragraph 1 or 2. 4. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5. 1. The following substances, namely -
2. Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -
(b) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position; (c) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring; (d) by fusion of ring A with a heterocyclic system.
3.
Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule. 1. - (1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. (2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6-nicotinoyldihydrocodeine), norcodeine and pholcodine and their respective salts. 2. Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. 3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health. 4. Any preparation of dextropropoxyphene, being a preparation designed for oral administration, containing not more than 135 milligrams of dextropropoxyphene (calculated as base) per dosage unit or with a total concentration of not more than 2.5% (calculated as base) in undivided preparations. 5. Any preparation of difenoxin containing, per dosage unit, not more than 0.5 milligrams of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin. 6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate. 7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount (by weight) of methylcellulose. 8. Any powder of ipecacuanha and opium comprising -
9.
Any mixture containing one or more of the preparations specified in paragraphs 1 to 8, being a mixture of which none of the other ingredients is a controlled drug.
(This note is not part of the Regulations) These Regulations revoke and re-enact, with amendments, the provisions of the Misuse of Drugs Regulations 1985, as amended. They provide certain exemptions from the provisions of the Misuse of Drugs Act 1971 which, subject to such regulations, prohibit the production, importation, exportation, possession and supply of controlled drugs, which are specified in Schedule 2 to that Act. The Regulations also make provision in relation to prescriptions, records and the furnishing of information concerning controlled drugs and for the supervision of the destruction of such drugs. Two changes of substance are made by the Regulations. One is the addition of thirty-five phenethylamine derivatives which are made subject to control under the Act of 1971 by virtue of the Misuse of Drugs Act 1971 (Modification) Order 2001 (S.I. 2001/3932) to Schedule 1 and one such derivative to Schedule 2. The other change is that the 33 benzodiazepines and 8 other substances formerly in Schedule 4 Part II are now in Part I of that Schedule. They are no longer exempt from the prohibition on importation and exportation or from the prohibition on possession when in the form of a medicinal product. The 54 anabolic substances formerly in Schedule 4 Part I are now in Part II of that Schedule. There are no changes to the controls which currently apply to these substances. Notes: [1] 1971 c. 38.back [5] S.I. 1972/1265 (N.I. 14).back
ISBN 0 11 039021 0
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||
| We welcome your comments on this site | © Crown copyright 2001 | Prepared 20 December 2001 |